Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals reported second-quarter 2026 Rezdiffra net revenues of $364.3 million, up 71% from $212.8 million a year earlier, with more than 49,000 patients on therapy and nearly $1.3 billion in trailing-12-month net sales.
The company highlighted three new U.S. resmetirom patents expected to protect key uses into 2042–2045 and initiated first-in-human dosing for oral GLP-1 candidate MGL-2086 in a Phase 1 trial supporting combination MASH therapy. Operating expenses rose to $420.6 million, leading to a net loss of $57.9 million, while cash, cash equivalents, restricted cash and marketable securities totaled $838.9 million as of June 30, 2026.
BlackRock, Inc. reports its beneficial ownership of common stock of Madrigal Pharmaceuticals, Inc. as of June 30, 2026. BlackRock beneficially owns 1,067,346 shares of common stock, representing 4.6% of the class. It holds 1,039,228 shares with sole voting power and all 1,067,346 shares with sole dispositive power, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no single person has more than five percent of Madrigal’s outstanding common shares.
Madrigal Pharmaceuticals President and CEO William John Sibold earned 50,000 shares of common stock on July 17, 2026 after meeting performance and service conditions under a one-time sign-on Performance RSU award. On July 20, 2026, the issuer sold 2,500 of these shares on his behalf in multiple automatic transactions at weighted-average prices between $542.22 and $555.10 per share to cover tax withholding obligations, and these sales were not at Sibold's discretion. The company is irrevocably obligated to issue the remaining earned shares to him on September 8, 2029.
Madrigal Pharmaceuticals, Inc. filed a notice of proposed sale of common stock under Form 144. The filing covers 2,500 shares of common stock held through Morgan Stanley Smith Barney LLC, with a proposed sale date of July 20, 2026 on the Nasdaq Stock Market. These shares were acquired upon the vesting of Performance Restricted Stock Units on July 17, 2026.
Madrigal Pharmaceuticals director Rebecca Taub reported new equity awards. She received 454 restricted stock units that vest on the earlier of June 17, 2027 or the company’s 2027 annual meeting, if she remains in service. She was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036, with the same vesting schedule. Following these awards, she holds 452,667 shares of common stock directly and 655,540 shares indirectly through SQN LLC, where she and her spouse are managing members and she disclaims beneficial ownership except for any pecuniary interest.
Madrigal Pharmaceuticals director Richard S. Levy received new equity awards. He was granted 454 shares of common stock as restricted stock units and 766 stock options with an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he continues in service. After the grants, he directly owns 22,469 common shares.
Madrigal Pharmaceuticals director Jacqualyn A. Fouse reported receiving new equity awards. She was granted 454 shares of common stock in the form of restricted stock units at no cost, increasing her direct common stock holdings to 1,551 shares.
She was also granted stock options covering 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036. Both the restricted stock units and the options vest 100% on the earlier of June 17, 2027 or the company’s 2027 annual meeting of stockholders, provided she continues in service with Madrigal through that date.
Madrigal Pharmaceuticals director James M. Daly reported awards of company equity as part of his compensation. He received 454 restricted stock units, which represent an equivalent number of common shares when they vest. He was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share.
Both the restricted stock units and the option vest 100% on the earlier of June 17, 2027 or the date of Madrigal’s 2027 annual meeting of stockholders, as long as he continues in service with the company. Following the grant, Daly directly holds 3,081 shares of common stock and the newly granted option on 766 shares.
Madrigal Pharmaceuticals director Daniel J. Brennan reported equity compensation awards. He received 404 shares of Common Stock as restricted stock units and a stock option for 681 shares at an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he remains in service. After these grants, Brennan directly holds 1,371 Common shares and 681 option shares.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Madrigal Pharmaceuticals reported equity compensation awards related to board service by representatives of Baker Bros.-affiliated funds. On June 17, 2026, a total of 908 restricted stock units (RSUs) and 1,532 non-qualified stock options tied to Madrigal common stock were granted in the aggregate to Julian C. Baker and Dr. Raymond Cheong, who serve on the board as representatives of 667, L.P. and Baker Brothers Life Sciences, L.P. The stock options have a strike price of $499.86, fully vest on the earlier of June 17, 2027 or the 2027 annual stockholder meeting, and expire 10 years from grant. The filing explains that the Baker funds have an indirect proportionate pecuniary interest in these securities, the investment adviser has voting and dispositive power, and various Baker entities disclaim beneficial ownership except to the extent of their pecuniary interest. No open-market purchases or sales are reported; all transactions are classified as grants or awards.